دورية أكاديمية
أعرض في EDS

Fibrinogen contribution to clot strength in patients with sepsis and hematologic malignancies and thrombocytopenia-a prospective, single-center, analytical, cross-sectional study.

التفاصيل البيبلوغرافية
العنوان: Fibrinogen contribution to clot strength in patients with sepsis and hematologic malignancies and thrombocytopenia-a prospective, single-center, analytical, cross-sectional study.
المؤلفون: Crochemore T; Intensive Care Department, Hospital Israelita Albert Einstein, São Paulo, Brazil.; Intensive Care Department, Hospital Moriah, São Paulo, Brazil.; Medical Department, Werfen Latam, São Paulo, Brazil., Scarlatescu E; Intensive Care Department, Bucharest and Fundeni Clinical Institute, University of Medicine and Pharmacy 'Carol Davila,' Bucharest, Romania., Görlinger K; Department of Anesthesiology and Intensive Care Medicine, University Hospital, Essen, Germany.; Medical Department, TEM Innovations/Werfen PBM, Munich, Germany., Rocha MDP; Intensive Care Department, Hospital Moriah, São Paulo, Brazil., Carlos de Campos Guerra J; Laboratory Department, Hospital Israelita Albert Einstein, São Paulo, Brazil.; Departament of Hematology, Hospital Israelita Albert Einstein, São Paulo, Brazil., Campêlo DHC; Departament of Hematology, Hospital Israelita Albert Einstein, São Paulo, Brazil., de Aranda VF; Laboratory Department, Hospital Israelita Albert Einstein, São Paulo, Brazil., Ricardi L; Laboratory Department, Hospital Israelita Albert Einstein, São Paulo, Brazil., Gomes GS; Laboratory Department, Hospital Israelita Albert Einstein, São Paulo, Brazil., Moura RA; Laboratory Department, Hospital Israelita Albert Einstein, São Paulo, Brazil., Assir FF; Research Department, Hospital Israelita Albert Einstein, São Paulo, Brazil., de Sá GRR; Departament of Hematology, Hospital Israelita Albert Einstein, São Paulo, Brazil., Lance MD; Department of Anesthesiology, Aga Khan University, Nairobi, Kenya., Hamerschlak N; Departament of Hematology, Hospital Israelita Albert Einstein, São Paulo, Brazil.
المصدر: Research and practice in thrombosis and haemostasis [Res Pract Thromb Haemost] 2024 Mar 01; Vol. 8 (2), pp. 102362. Date of Electronic Publication: 2024 Mar 01 (Print Publication: 2024).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Elsevier Country of Publication: United States NLM ID: 101703775 Publication Model: eCollection Cited Medium: Internet ISSN: 2475-0379 (Electronic) Linking ISSN: 24750379 NLM ISO Abbreviation: Res Pract Thromb Haemost Subsets: PubMed not MEDLINE
أسماء مطبوعة: Publication: 2023- : [New York] : Elsevier
Original Publication: Hoboken, NJ : John Wiley & Sons, Inc., [2017]-
مستخلص: Background: Patients with hematological malignancies (HM) frequently present thrombocytopenia and higher risk of bleeding. Although transfusion is associated with higher risk of adverse events and poor outcomes, prophylactic transfusion of platelets is a common practice to prevent hemorrhagic complications. Thromboelastometry has been considered a better predictor for bleeding than isolated platelet counts in different settings. In early stages of sepsis, hypercoagulability may occur due to higher fibrinogen levels.
Objectives: To evaluate the behavior of coagulation in patients with HM who develop sepsis and to verify whether a higher concentration of fibrinogen is associated with a proportional increase in maximum clot firmness (MCF) even in the presence of severe thrombocytopenia.
Methods: We performed a unicentric analytical cross-sectional study with 60 adult patients with HM and severe thrombocytopenia, of whom 30 had sepsis (sepsis group) and 30 had no infections (control group). Coagulation conventional tests and specific coagulation tests, including thromboelastometry, were performed. The main outcome evaluated was MCF.
Results: Higher levels of fibrinogen and MCF were found in sepsis group. Both fibrinogen and platelets contributed to MCF. The relative contribution of fibrin was significantly higher (60.5 ± 12.8% vs 43.6 ± 9.7%; P  < .001) and that of platelets was significantly lower (39.5 ± 12.8% vs 56.4 ± 9.7%; P  < .001) in the sepsis group compared with the control group.
Conclusion: Patients with sepsis and HM presented higher concentrations of fibrinogen than uninfected patients, resulting in greater MCF amplitudes even in the presence of thrombocytopenia.
(© 2024 The Author(s).)
References: Anaesthesia. 2017 Apr;72(4):519-531. (PMID: 28052313)
Korean J Anesthesiol. 2019 Aug;72(4):297-322. (PMID: 31096732)
Semin Hematol. 2001 Oct;38(4 Suppl 11):20-6. (PMID: 11727282)
Curr Opin Crit Care. 2023 Dec 1;29(6):702-712. (PMID: 37861185)
J Cardiothorac Vasc Anesth. 2023 Jun;37(6):942-947. (PMID: 36933991)
Biomed Rep. 2018 Nov;9(5):453-457. (PMID: 30402229)
Blood Coagul Fibrinolysis. 2019 Jul;30(5):181-187. (PMID: 31157682)
Anesth Analg. 2022 Sep 1;135(3):476-488. (PMID: 35147598)
Medicine (Baltimore). 2016 Aug;95(31):e4514. (PMID: 27495106)
Einstein (Sao Paulo). 2017 Jul-Sep;15(3):380-385. (PMID: 28614427)
Minerva Anestesiol. 2022 Jul-Aug;88(7-8):573-579. (PMID: 35381835)
J Trauma Acute Care Surg. 2023 Jun 1;94(6):857-862. (PMID: 36787438)
Am Surg. 2012 Jan;78(1):1-8. (PMID: 22273282)
Int J Cardiol. 2017 Dec 15;249:96-100. (PMID: 28986056)
Transfusion. 2020 Oct;60 Suppl 6:S86-S100. (PMID: 33089937)
Semin Thromb Hemost. 2021 Jul;47(5):569-580. (PMID: 34058766)
Ann Intensive Care. 2019 Jan 30;9(1):19. (PMID: 30701381)
Blood Transfus. 2018 May;16(3):235-243. (PMID: 29517967)
Anesth Analg. 2015 Oct;121(4):868-878. (PMID: 26378699)
Transfus Med. 2016 Aug;26(4):291-6. (PMID: 27238953)
Br J Haematol. 2019 Apr;185(2):209-218. (PMID: 30828800)
JAMA. 2016 Feb 23;315(8):801-10. (PMID: 26903338)
Can J Anaesth. 2018 Dec;65(12):1333-1347. (PMID: 30194674)
Acta Anaesthesiol Scand. 2012 Nov;56(10):1277-90. (PMID: 22897591)
J Thromb Haemost. 2007 May;5(5):1019-25. (PMID: 17461931)
J Crit Care. 2013 Jun;28(3):317.e1-11. (PMID: 23159146)
Intensive Care Med. 2017 Apr;43(4):581-583. (PMID: 28220224)
Eur J Pediatr. 2021 Dec;180(12):3455-3470. (PMID: 34131816)
Iran J Pathol. 2018 Spring;13(2):272-275. (PMID: 30697298)
Crit Care Med. 2000 Sep;28(9 Suppl):S44-8. (PMID: 11007197)
Clin Infect Dis. 2003 May 15;36(10):1259-65. (PMID: 12746771)
Clin Chem Lab Med. 2019 Nov 26;57(12):1808-1817. (PMID: 31465290)
J Thromb Haemost. 2014 Feb;12(2):197-205. (PMID: 24261582)
Am J Hematol. 2019 Jul;94(7):833-839. (PMID: 30945756)
Transplant Proc. 2015 Jul-Aug;47(6):1890-5. (PMID: 26293068)
Biochem Med (Zagreb). 2021 Jun 15;31(2):020709. (PMID: 34140832)
Blood. 1996 Aug 1;88(3):881-6. (PMID: 8704245)
Crit Care. 2010;14(5):R178. (PMID: 20929576)
J Trauma Acute Care Surg. 2014 Feb;76(2):255-6; discussion 262-3. (PMID: 24458031)
Int J Mol Sci. 2021 Apr 01;22(7):. (PMID: 33916027)
Br J Anaesth. 2013 Feb;110(2):222-30. (PMID: 23112213)
Pediatr Crit Care Med. 2021 Nov 1;22(11):969-977. (PMID: 33965991)
Eur Heart J. 2022 Oct 14;43(39):3826-3924. (PMID: 36017553)
J Thromb Haemost. 2018 Apr;16(4):652-662. (PMID: 29363269)
Life (Basel). 2023 Jan 28;13(2):. (PMID: 36836706)
Eur J Haematol. 2021 May;106(5):662-672. (PMID: 33544940)
Mediterr J Hematol Infect Dis. 2010 Aug 13;2(3):e2010024. (PMID: 21415977)
Nat Rev Dis Primers. 2021 Apr 29;7(1):30. (PMID: 33927200)
Br J Haematol. 2011 Aug;154(4):425-40. (PMID: 21615375)
Biology (Basel). 2023 Sep 26;12(10):. (PMID: 37886991)
Crit Care. 2014 Feb 10;18(1):R30. (PMID: 24512650)
Clin Appl Thromb Hemost. 2018 Sep;24(6):993-997. (PMID: 28950719)
Anaesthesiol Intensive Ther. 2016;48(5):352-359. (PMID: 27824218)
Blood Adv. 2023 Nov 28;7(22):7056-7066. (PMID: 37756519)
J Clin Med. 2022 Mar 04;11(5):. (PMID: 35268498)
Curr Opin Anaesthesiol. 2015 Apr;28(2):227-36. (PMID: 25590467)
Hamostaseologie. 2013;33(1):51-61. (PMID: 23258612)
Semin Thromb Hemost. 2013 Jul;39(5):559-66. (PMID: 23625756)
Shock. 2013 Jan;39(1):45-9. (PMID: 23247121)
Cochrane Database Syst Rev. 2016 Aug 05;(8):CD010864. (PMID: 27494075)
Shock. 2011 Apr;35(4):339-42. (PMID: 21068699)
J Cardiothorac Vasc Anesth. 2014 Apr;28(2):210-6. (PMID: 24630470)
Scand J Trauma Resusc Emerg Med. 2016 Oct 3;24(1):114. (PMID: 27716278)
Front Immunol. 2018 Jun 18;9:1218. (PMID: 29967603)
Clin Chem. 2011 Sep;57(9):1256-62. (PMID: 21719689)
Transfusion. 2017 Jun;57(6):1325-1327. (PMID: 28594141)
Crit Care. 2009;13(2):R42. (PMID: 19331653)
Immunobiology. 2013 Apr;218(4):470-6. (PMID: 22749979)
Transfus Apher Sci. 2015 Aug;53(1):64-8. (PMID: 25818995)
Anesth Analg. 2012 Feb;114(2):261-74. (PMID: 21965371)
Crit Care. 2010;14(2):R55. (PMID: 20374650)
Hamostaseologie. 2006 Aug;26(3 Suppl 1):S20-9. (PMID: 16953288)
Vox Sang. 2021 Oct;116(9):998-1004. (PMID: 33772793)
Transfus Apher Sci. 2009 Oct;41(2):139-44. (PMID: 19744888)
Front Pediatr. 2021 Jun 02;9:676565. (PMID: 34150689)
Clin Appl Thromb Hemost. 2022 Jan-Dec;28:10760296221101386. (PMID: 35549920)
Front Pediatr. 2022 Oct 06;10:1004727. (PMID: 36275071)
J Thromb Haemost. 2005 Apr;3(4):692-4. (PMID: 15842354)
Blood. 1998 May 15;91(10):3601-6. (PMID: 9572994)
Crit Care. 2018 Oct 27;22(1):271. (PMID: 30367640)
J Thromb Haemost. 2020 Mar;18(3):740-747. (PMID: 32112533)
فهرسة مساهمة: Keywords: hematological malignancies; platelet transfusion; sepsis; thrombocytopenia; thromboelastometry
تواريخ الأحداث: Date Created: 20240426 Latest Revision: 20240427
رمز التحديث: 20240427
مُعرف محوري في PubMed: PMC11043640
DOI: 10.1016/j.rpth.2024.102362
PMID: 38666064
قاعدة البيانات: MEDLINE
الوصف
تدمد:2475-0379
DOI:10.1016/j.rpth.2024.102362